Related Experiment Videos
Levodopa, melanoma, and Parkinson's disease
W J Weiner1, C Singer, J R Sanchez-Ramos
1University of Miami School of Medicine, Department of Neurology, FL 33136.
Neurology
|April 1, 1993
Summary
Levodopa (L/C) is often cautioned against in Parkinson's disease (PD) patients with melanoma. However, evidence suggests L/C is safe and may even have antitumor effects in these patients.
Area of Science:
- Neurology
- Dermatology
- Oncology
Background:
- Physicians' Desk Reference and prior reports advise against levodopa use in Parkinson's disease (PD) patients with melanoma.
- Literature review indicates only anecdotal evidence supports a link between levodopa and melanoma.
- Levodopa exhibits potential antitumor effects on melanoma.
Purpose of the Study:
- To critically evaluate the contraindication of levodopa in PD patients with melanoma.
- To assess the safety and efficacy of levodopa/carbidopa (L/C) in PD patients with a history of melanoma.
Main Methods:
- Literature review of existing reports on levodopa and melanoma.
- Clinical observation of nine Parkinson's disease patients with melanoma treated with levodopa/carbidopa (L/C).
Main Results:
- Anecdotal evidence is the sole support for a levodopa-melanoma link.
- Levodopa demonstrated an antitumor effect on melanoma.
- Nine PD patients with melanoma tolerated L/C treatment safely.
Conclusions:
- The contraindication of levodopa in PD patients with melanoma is not supported by robust evidence.
- Levodopa/carbidopa (L/C) can be safely administered to PD patients with a history of melanoma.
- Further research is warranted to explore levodopa's potential therapeutic role in melanoma treatment.